XNAS · Healthcare · Biotechnology
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.26 | -0.31 | -19.23% | $0 | ❌ Miss | -1.28% | -1.98% | — |
| 2026-03-05 | Q4 2025 | -0.28 | -0.23 | +17.86% | $0 | ✅ Beat | +1.94% | +2.31% | -3.96% |
| 2025-11-06 |
| Q3 2025 |
| -0.23 |
| -0.23 |
| +0.00% |
| $0 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-02-27 | Q4 2024 | -0.22 | -0.17 | +22.73% | $0 | ✅ Beat | -4.88% | -0.94% | +3.57% |
| 2024-11-14 | Q3 2024 | -0.25 | -0.23 | +8.00% | $0 | ✅ Beat | +1.34% | +7.25% | -8.58% |
| 2024-09-03 | Q2 2024 | -0.23 | -0.20 | +13.04% | $0 | ✅ Beat | -13.66% | -18.35% | -33.44% |
| 2024-05-03 | Q1 2024 | -0.22 | -0.15 | +31.82% | $0 | ✅ Beat | +0.09% | +9.67% | +21.58% |
| 2024-02-29 | Q4 2023 | -0.20 | -0.21 | -5.00% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.